


RESEARCH REPORT



ANTIBIOTIC RESISTANCE MARKETS - THERAPEUTICS. By Pathogen and Therapy Type. With Situation Analysis, Executive and Investor Guides

2023 to 2027





Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the X-Ray market the next.

HOWE SOUND RESEARCH

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Table of Contents

1	Market Guides.....	19
1.1	Strategic Situation Analysis.....	20
1.2	Guide for Executives and Business Development Staff.....	24
1.3	Guide for Management Consultants and Investment Advisors.....	26
2	Introduction and Market Definition.....	27
2.1	Antimicrobial Resistance.....	28
2.2	Defining the Opportunity.....	31
2.2.1	Revenue Market Size.....	31
2.3	Methodology.....	33
2.3.1	Methodology.....	33
2.3.2	Sources.....	33
2.3.3	Authors.....	34
2.4	U.S. Antibiotic Markets - Perspective.....	35
2.4.1	U.S. Outpatient Use of Antibiotics.....	36
2.4.2	U.S. Pharmaceutical Spending.....	39
3	Overview of a Dynamic Market.....	42

3.1	Market Players – Roles & Impacts.....	43
3.1.1	Drug manufacturers - Larger/pharmaceutical	44
3.1.2	Drug manufacturers - Generic	45
3.1.3	Contract Research and Manufacturing	46
3.1.4	In Vitro Diagnostics Industry	47
3.1.5	Drug Marketing Companies	49
3.1.6	Biotechnology Companies	49
3.1.7	Regulatory Bodies	50
3.2	Understanding Antimicrobial Resistance	52
3.2.1	What is Antimicrobial Resistance (AMR)	53
3.2.2	Bacteria and Other Microbes.....	54
3.2.3	The History of Antibiotics.....	62
3.2.4	The Role of Animal Husbandry.....	67
3.2.5	The Implications of Horizontal Transfer.....	68
3.2.6	The Threat of AMR	70
3.3	The Changing Road to New Antibiotics & Technologies.....	73
3.4	The Key Role of Diagnostics in AMR.....	76
4	The Market Opportunity of AMR.....	78
4.1	The Key Large Market Opportunities in AMR	79

4.1.1	Streptococcus Pneumoniae (DRSP)	80
4.1.2	Campylobacter (DRC)	84
4.1.3	Clostridium Difficile (CD)	88
4.1.4	Staphylococcus aureus (MRSA)	92
4.1.5	Neisseria gonorrhoeae (DRNG)	96
4.1.6	Salmonella (DRNTS)	100
4.2	Therapeutic Technology Development Opportunities	104
4.2.1	Using Viruses Against Bacteria	105
4.2.2	Hydrolytic Enzymes Join the Fight	107
4.2.3	Antibodies	109
4.2.4	Vaccines.....	112
4.2.5	Probiotic Technology	114
4.2.6	Peptides vs. Pathogens	115
4.2.7	Mining Obsolete Science	116
4.2.8	CRISPR Antibiotics.....	116
5	Antibiotic Resistance Recent Developments	117
5.1.1	Recent Developments – Importance and How to Use This Section	118
5.1.2	Importance of These Developments	118

5.1.3	How to Use This Section	118
5.2	Bacteriophage May Combat AMR	118
5.3	Shionogi to Acquire Qpex Biopharma	123
5.4	Adaptive Phage Therapeutics to Fight Antibiotic Resistance.....	124
5.5	Smartbax to create next-generation antibiotics.....	125
5.6	Startup Solu raises €1M to combat AMR	127
5.7	Akthelia Pharma and University of Iceland to Combat AMR.....	130
5.8	WHO warns of too few new Antibiotics.....	131
5.9	Bactobio Raises £6 Million To Discover Novel Antimicrobials	136
5.10	AMR triggers race to develop phages.....	138
5.11	AMR Pandemic Overlooked.....	146
5.12	New resistance-busting antibiotic combination	150
5.13	CDC Awards \$22M to Combat Antimicrobial Resistance	154
5.14	Antibiotic resistance outwitted by supercomputers.....	156
5.15	STIs Reach Record Highs.....	159
5.16	New research using nanoparticles to bolster waning antibiotics	172
5.17	OpGen Receives FDA Clearance for AMR Panel.....	175
5.18	CDC Updates STI Diagnosis, Treatment Guidelines	177

5.19	Positive associations between AM use in animals and AMR in humans	182
5.20	PEW Antibiotic Pipeline Findings	186
6	Key Biotechnology Companies and Their Technology	189
6.1	Melinta Therapeutics.....	190
6.2	Arsanis	192
6.3	Phage Technologies S.A	194
6.4	Westway Health.....	196
6.5	Tetraphase Pharmaceuticals.....	198
6.6	BioVersys GmbH.....	200
6.7	Nabriva Therapeutics.....	202
6.8	Macrolide Pharmaceuticals	204
6.9	Nemesis Bioscience	206
6.10	C3J Therapeutics, Inc.....	208
6.11	EpiBiome	210
6.12	discuva.....	212
6.13	SmartPhage.....	214
6.14	AmpliPhi Biosciences.....	215
6.15	Pherecydes Pharma.....	217

6.16	Micreos.....	219
6.17	Procarta Biosystems	221
6.18	Lumavita.....	224
6.19	Madam Therapeutics	226
6.20	Priaxon	228
6.21	Biolytx Pharmaceuticals.....	229
6.22	AntibioTx	231
6.23	Xellia Pharmaceutials.....	233
6.24	Paratek Pharmaceuticals.....	235
6.25	Synereca Pharmaceuticals.....	237
6.26	Allegra Therapeutics	239
6.27	Fixed Phage	241
6.28	Enanta Pharmaceuticals, Inc.	243
6.29	Demuris	245
6.30	Prommune	247
6.31	Biosergen	249
6.32	Innovation Pharmaceuticals.....	250
6.33	Aviragen Therapeutics.....	251
6.34	Achillion Pharmaceuticals.....	253

6.35	ImmunNovative Developments, S.L.....	255
6.36	Achaogen, Inc.....	256
6.37	SelectX Pharmaceuticals, Inc.....	258
6.38	TaiGen Biotechnology Co., Ltd.	260
6.39	Theravance Biopharma.....	261
6.40	Abbvie	263
6.41	KYORIN Pharmaceutical Co.,Ltd.....	265
6.42	Iterum Therapeutics Limited.....	267
6.43	Forge Therapeutics.....	269
6.44	Alopexx Vaccine LLC.....	271
6.45	Integrated Biotherapeutics.....	273
6.46	Hennepin Life Sciences.....	275
6.47	Fedora Pharmaceuticals Inc.	277
6.48	Contrafect Corporation	279
6.49	Basilea Pharmaceutica Ltd.....	281
6.50	AiCuris	284
6.51	RedHill Biopharma	286
6.52	Redx Pharma Plc/ Redx Anti Infections Ltd.....	288
6.53	ABAC Therapeutics	289

6.54	Alaxia SAS	290
6.55	Antabio S.A.S.....	291
6.56	Auspherix Ltd.....	293
6.57	BioFilm Pharma.....	295
6.58	Centauri Therapeutics Ltd.....	297
6.59	Combioxin SA.....	299
6.60	Da Volterra	301
6.61	Debiopharm International SA	303
6.62	Deinobiotics/Deinove	305
6.63	Destiny Pharma plc	307
6.64	Eligo Bioscience	309
6.65	Helperby Therapeutics Ltd	311
6.66	Karveel Pharmaceuticals	313
6.67	MaaT Pharma	315
6.68	Motif BioSciences, Inc / Motif Bio PLC.....	317
6.69	Mutabilis SAS.....	320
6.70	Neem Biotech Ltd.....	322
6.71	Northern Antibiotics Oy (Ltd)	324
6.72	Nosopharm.....	326

6.73	NovaBiotics Ltd	328
6.74	Phico Therapeutics Ltd	330
6.75	Polyphor Ltd	333
6.76	QureTech Bio AB	334
6.77	SetLance srl	335
6.78	Ultupharma AB.....	336
6.79	Vaxdyn.....	338
6.80	Vibiosphen.....	340
6.81	Bioaster	341
6.82	Vivexia.....	342
6.83	KBP Biosciences	343
6.84	Absynth Biologics.....	345
6.85	Spero Therapeutics.....	346
6.86	Merck	348
6.87	Symphogen.....	351
6.88	Warp Drive Bio.....	353
6.89	Johnson & Johnson (Janssen).....	356
6.90	Pfizer	359
6.91	Allergan	361

6.92	GlaxoSmithKline	363
6.93	Novartis	365
6.94	Gilead Sciences.....	367
6.95	AstraZeneca.....	369
6.96	Sanofi	371
6.97	Shionogi Inc.....	373
6.98	Cipla	375
6.99	DSM Sinochem Pharmaceuticals	377
6.100	Wockhardt Ltd.....	378
6.101	VenatoRx Pharmaceuticals	380
6.102	MicuRx.....	383
6.103	Entasis Therapeutics	385
6.104	Merlion Pharmaceuticals	386
6.105	Aridis Pharmaceuticals Inc.....	388
6.106	The Therapeutics Race – Summary of Companies Research Areas	390
7	Global Market Size	392
7.1	Global Market by Country	393
7.2	Global Market by Pathogen	395

7.3	Global Market by Technology.....	400
8	Market Sizes by Pathogen	406
8.1	DRSP Market.....	407
8.2	DRC Market.....	409
8.3	CD Market.....	411
8.4	MRSA Market.....	413
8.5	DRNG Market.....	415
8.6	DRNTS Market.....	417
8.7	Other Pathogen Market	419
9	Market Sizes by Technology	421
9.1	Antibiotics Market.....	422
9.2	Phage Market	424
9.3	Pep/Lys Market	426
9.4	Antibodies Market	428
9.5	Vaccine Market.....	430
9.6	Other Technology Market	432
10	The Future of AMR.....	434
11	Appendices.....	436
11.1	United States Medicare System: Top Selling Drugs 2011-2015	436

Table of Tables

Table 1 USA - Outpatient Use of Antibiotics by Class	37
Table 2 USA - Outpatient Use of Antibiotics Top 5	38
Table 3 Market Players by Type.....	43
Table 4 Known Human Pathogenic Diseases.....	57
Table 5 The Key Market Opportunities	79
Table 6 - Market Potential DRSP Therapeutic	82
Table 7 - Market Potential DRC Therapeutic	86
Table 8 Eight Technologies under development.....	104
Table 9 Antibodies Approved for Infectious Disease Treatment	109
Table 10 Therapeutic Technology Research - # of Companies.....	391
Table 11 Global Market by Country	393
Table 12 Global Market by Pathogen.....	395
Table 13 Global Market by Technology.....	400
Table 14 DRSP Segment by Country	407
Table 15 DRC Segment by Country.....	409

Table 16 CD Segment by Country	411
Table 17 MRSA Segment by Country.....	413
Table 18 DRNG Segment by Country	415
Table 19 DRNTS Segment by Country.....	417
Table 20 Other Pathogen Segment by Country	419
Table 21 Antibiotics Segment by Country	422
Table 22 Phage Segment by Country	424
Table 23 Pep/Lys Segment by Country	426
Table 24 Antibodies Segment by Country	428
Table 25 Vaccine Segment by Country.....	430
Table 26 Other Technology Segment by Country	432
Table 27 2011 to 2015 Top Selling Drugs.....	436

Table of Figures

Figure 1 Pharmaceutical Spending Trends.....	40
Figure 2 AMR and Antibiotic Introduction	66
Figure 3 The Death Toll of AMR.....	71
Figure 4 Phage T4 Anatomy and Infection Cycle	106
Figure 5 Key Global Markets.....	394
Figure 6 Pathogen Share by Year	396
Figure 7 Pathogen Segment Growth Rates.....	397
Figure 8 Segment Share Shifts.....	398
Figure 9 Market Share Start Year.....	399
Figure 10 Market Share End Year.....	399
Figure 11 Technology Share by Year.....	401
Figure 12 Pathogen Segment Growth Rates.....	402
Figure 13 Segment Share Shifts.....	403
Figure 14 Market Share Start Year.....	404
Figure 15 Market Share End Year.....	405
Figure 16 DRSP vs. Total Market Growth.....	408

Figure 17 DRC vs. Total Market Growth.....	410
Figure 18 CD vs. Total Market Growth.....	412
Figure 19 MRSA vs. Total Market Growth.....	414
Figure 20 DRNG vs. Total Market Growth.....	416
Figure 21 DRNTS vs. Total Market Growth.....	418
Figure 22 Other Pathogen vs. Total Market Growth.....	420
Figure 23 Antibiotics vs. Total Market Growth.....	423
Figure 24 Phage vs. Total Market Growth.....	425
Figure 25 Pep/Lys vs. Total Market Growth.....	427
Figure 26 Antibodies vs. Total Market Growth.....	429
Figure 27 Vaccine vs. Total Market Growth.....	431
Figure 28 Other Technology vs. Total Market Growth.....	433